Reliance Global Group Stock Price, News & Analysis
Why is EZRA Stock Up Today?
Company Description
Reliance Global Group (NASDAQ: EZRA) is a publicly traded insurance brokers company in the Insurance Agents, Brokers & Service sector. The company has a market capitalization of $3.7M, ranking #6,913 among all listed U.S. companies by market cap.
EZRA stock has declined 33.8% over the past year. Shares last traded at $0.1700.
On a trailing twelve-month basis, Reliance Global Group reported revenue of $12.4M with net income of -$7.0M and diluted earnings per share of $-1.28. The company operates at a net profit margin of -56.2%.
This page provides a comprehensive overview of EZRA stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Reliance Global Group (EZRA) stock last traded at $0.1700, up 4.47% from the previous close. Over the past 12 months, the stock has lost 33.8%. At a market capitalization of $3.7M, EZRA is classified as a micro-cap stock with approximately 21.3M shares outstanding.
EZRA Rankings
Latest News
Reliance Global Group has 10 recent news articles, with the latest published today. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include conferences, earnings, acquisition. View all EZRA news →
SEC Filings
Reliance Global Group has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 424B3, 1 Form EFFECT, 1 Form POS AM. The most recent filing was submitted on May 4, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all EZRA SEC filings →
Insider Radar
Insider buying activity at Reliance Global Group over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Reliance Global Group generated $12.4M in revenue over the trailing twelve months, operating income reached -$9.0M (-72.5% operating margin), and net income was -$7.0M, reflecting a -56.2% net profit margin. Diluted earnings per share stood at $-1.28. The company generated -$3.1M in operating cash flow. With a current ratio of 1.78, the balance sheet reflects a strong liquidity position.
Upcoming Events
Warrants expiration
Warrants expiration
Reliance Global Group has 2 upcoming scheduled events. The next event, "Warrants expiration", is scheduled for January 29, 2028 (in 635 days). 2 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the EZRA stock price.
Short Interest History
Short interest in Reliance Global Group (EZRA) currently stands at 548.3 thousand shares, down 62.2% from the previous reporting period, representing 2.8% of the float. Over the past 12 months, short interest has decreased by 23.4%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Reliance Global Group (EZRA) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
EZRA Company Profile & Sector Positioning
Reliance Global Group (EZRA) operates in the Insurance Brokers industry within the broader Insurance Agents, Brokers & Service sector and is listed on the NASDAQ.
Reliance Global Group (NASDAQ: EZRA) completed a strategic investment through its LifeSci Global biotech division in Innervate Radiopharmaceuticals on May 4, 2026.
LifeSci Global agreed to acquire 421,053 shares at $4.75 (~$2.0 million total), with $500,000 funded at closing and staged follow-on funding rights. Innervate’s lead asset is 18F-mFBG for PET imaging in neuroblastoma; initial market opportunity ~$250M, with potential >$1B expansion markets and possible Priority Review Voucher upside. Interested directors recused; certain directors hold equity in LifeSci Global.